General contact

Novartis Pharmaceuticals UK Limited
UK Head Office
Frimley Business Park Frimley
Camberley Surrey GU16 7SR

+44 1276 692255
+44 1276 692508
Monday - Friday,
8:30 - 17:30


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Novartis UK Press Office
Press Office enquiries only

+44 1276 698691

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine. More information

Product Information

For enquiries contact

+44 1276 698 370

pane 4 content



New data from PARADIGM-HF show Novartis’ heart failure drug LCZ696 keeps patients alive longer and in better health than current gold standard ACE inhibitor (enalapril)

21 November 2014 New analyses was presented at the American Heart Association (AHA) Scientific Sessions show.

Novartis is leading the way with a new generation targeted psoriasis treatment

21 November 2014 CosentyxTM (secukinumab) the first IL-17A inhibitor with positive CHMP opinion

Royal College of Ophthalmologists and the BMJ editorial

21 November Our response to Royal College of Ophthalmologists and the BMJ editorial.

Novartis works with NHS in Bristol to launch a new eye service in the local community

20 November 2014 People in Bristol and the surrounding area will now be able to benefit from a new eye service based in the community, allowing care for common and treatable eye conditions to be provided closer to home.

Novartis announces its results for the third quarter of 2014.

18 November 2014 Visit the event centre for full information.

Novartis responds to the Ebola outbreak

18 November 2014 As the Ebola outbreak in West Africa continues to expand with isolated cases now being reported in Europe and North America, Novartis and its employees are contributing aid and pursuing research to help fight the deadly virus.

Top Links